LeMaitre Vascular Inc (LMAT) Shares Bought by BlackRock Inc.

BlackRock Inc. raised its holdings in LeMaitre Vascular Inc (NASDAQ:LMAT) by 4.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,425,454 shares of the medical instruments supplier’s stock after acquiring an additional 93,615 shares during the quarter. BlackRock Inc. owned approximately 12.56% of LeMaitre Vascular worth $81,202,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Piedmont Investment Advisors LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth $119,000. Dynamic Technology Lab Private Ltd bought a new position in shares of LeMaitre Vascular during the 1st quarter worth $215,000. Creative Planning bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth $220,000. Citadel Advisors LLC bought a new position in shares of LeMaitre Vascular during the 1st quarter worth $241,000. Finally, Quantitative Systematic Strategies LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth $263,000. 79.75% of the stock is currently owned by institutional investors.

Shares of NASDAQ LMAT opened at $28.41 on Tuesday. The firm has a market cap of $748.16 million, a P/E ratio of 33.03, a P/E/G ratio of 2.42 and a beta of 0.63. LeMaitre Vascular Inc has a 1-year low of $26.99 and a 1-year high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.21. The firm had revenue of $24.17 million during the quarter, compared to analysts’ expectations of $26.06 million. LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%. As a group, analysts anticipate that LeMaitre Vascular Inc will post 1.07 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 6th. Investors of record on Tuesday, November 20th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date is Monday, November 19th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 32.56%.

In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 39,820 shares of the stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $37.34, for a total value of $1,486,878.80. Following the completion of the sale, the chairman now directly owns 3,085,291 shares in the company, valued at $115,204,765.94. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman George W. Lemaitre sold 14,180 shares of the stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $37.61, for a total value of $533,309.80. Following the completion of the sale, the chairman now owns 3,118,266 shares of the company’s stock, valued at $117,277,984.26. The disclosure for this sale can be found here. Insiders have sold a total of 97,506 shares of company stock valued at $3,608,759 over the last 90 days. 20.30% of the stock is currently owned by company insiders.

LMAT has been the topic of a number of recent research reports. BidaskClub downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Saturday, September 8th. Roth Capital upgraded LeMaitre Vascular from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $39.00 to $34.00 in a research note on Monday. Canaccord Genuity decreased their price objective on LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating for the company in a research note on Monday. Lake Street Capital cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday. Finally, ValuEngine upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Tuesday, July 24th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. LeMaitre Vascular currently has a consensus rating of “Hold” and a consensus price target of $36.63.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: What is a Stop Order?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply